Abstract:TPS5112 Background: Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies but application of CAR T cell therapy in solid malignancies remains a high priority. We previously demonstrated initial safety of a PSCA CAR T cells in patients with mCRPC following a reduced lymphodepletion regimen (LD) in a phase 1 trial (NCT03873805). There was preliminary evidence of anti-tumor activity (Dorff 2023) but escalation was not pursued due to concerns of toxicity. Additional dose exploration is needed. Preclinical work suggests that radiation therapy directed to tumor sites modifies the tumor microenvironment providing rationale for combining metastasis directed radiation therapy (MDRT) with CAR T cell therapy. The phase 1b dose exploration study aims to test a multi-dose strategy and whether the addition of MDRT could further enhance response. Methods: This is a single-center, open-label, phase Ib trial for patients with PSCA+ mCRPC. Key inclusion criteria are a diagnosis of mCRPC with evaluable disease, at least one area of metastasis amenable for radiation (for the MDRT cohort), PSCA expression by immunohistochemistry on archival tissue, and prior progression on abiraterone or enzalutamide or both; prior taxane chemotherapy is allowed. The primary objective will be to assess the feasibility, safety, and activity of PSCA CAR T cell therapy. Primary endpoints will include evaluation of toxicity through DLT’s and activity through rate of PSA50 and objective responses. Secondary endpoints will include overall survival, progression-free survival (PCWG3 criteria), measurement of CAR T cell and cytokine kinetics, and T cell infiltration in pre- and post-treatment tumor biopsies. Exploratory endpoints will include phenotypes and frequencies of immune cell subsets in peripheral blood pre- and post-therapy, gene expression of CTCs, CAR immunogenicity by the presence of anti CAR antibodies or T cell mediated immune responses, urine analysis, cfDNA whole exome sequencing, and phenotype tumor infiltrating lymphocytes. This study includes 2 treatment plans (TP). The participants on TP 1 will receive 50 million PSCA CAR T cells every 2 weeks for up to 6 doses after LD chemotherapy. Based on these results, the number of cycles of CAR T will be determined for TP2. Participants on TP 2 will receive PSCA CAR T therapy after MDRT and LD. The first 3 participants on each TP will be staggered, all further participants will be treated in cohorts of 3. Toxicities will be monitored based on a Wald sequential probability ratio test. Rates and associated 90% Clopper and Pearson binomial confidence limits will be estimated for DLTs within the DLT period, disease response based on PSA50/RECIST/PCWG3 criteria, PFS at 6 months, and OS at 1 year. The results will be used to identify the optimal strategy to move to phase 2. The study is currently open to enrollment. Clinical trial information: NCT05805371 .

A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer.

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer

A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.

A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.

DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer

A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.

A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.

Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing.

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.

A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.

Time to Second Progression (PFS2) in Patients (pts) from TITAN with Metastatic Castration-Sensitive Prostate Cancer (mcspc) by First Subsequent Therapy (hormonal Vs. Taxane)

Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study

A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).